about
MDMA and the “Ecstasy Paradigm”Abuse of amphetamines and structural abnormalities in the brainToxicity of amphetamines: an updateMethylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?Role of the serotonin 5-HT(2A) receptor in learningContributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicologyContent of ecstasy in the Netherlands: 1993-2008A review of nanoparticle functionality and toxicity on the central nervous systemCharacteristics of ecstasy users in Sãio Paulo, Brazil.The preclinical pharmacology of mephedrone; not just MDMA by another name.Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats.A Qualitative Descriptive Study of Perceived Sexual Effects of Club Drug Use in Gay and Bisexual Men.Behavioral sensitization and cross-sensitization between methylphenidate amphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) in female SD rats.21-year-old woman with palpitations and vomitingThe role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivativesA mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity.The effects of stereotype threat on cognitive function in ecstasy users.Perceived risk associated with ecstasy use: a latent class analysis approach.Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in ratsChronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptorsA clinical crossroads for MDMA.MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memoryIs recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms?Tri-city study of Ecstasy use problems: a latent class analysis.Ecstasy (MDMA) and oral health.Secondary psychoses: an update.A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs).Psychiatric disorders and their correlates among young adult MDMA users in Ohio.The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis.Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.MDMA/Ecstasy use among young people in Ohio: perceived risk and barriers to intervention.Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs.Oral health sensations associated with illicit drug abuse.Memory and mood during the night and in the morning after repeated evening doses of MDMA.
P2860
Q21558618-F758681E-464A-4343-9F63-0A366806DF7CQ22241673-34267334-59A5-4669-99B3-378B6A0DDF20Q22252794-10DB1DA6-0272-4638-8E8B-E1725AF371A8Q24627529-764171D5-68EF-475E-8B37-CBF6A74A4518Q24685023-19B9FCFB-E0AF-4C97-A5D5-8D9BAE55EE6AQ27005695-D8808FB8-783F-4646-9C7E-9947B8E77691Q28260437-FECD4464-D3C5-48DF-BFB5-E56DB29BAD2FQ28383491-A5573053-251F-4330-95B4-D6D56E509A3BQ30350392-A58D6B55-CB0C-4D01-A088-4E663F8A20D4Q30412911-C44DA85F-18D6-4185-840F-013083C75A0FQ33328978-624B846C-1E54-459E-A33F-265A10B9B332Q33677137-B88A2A9F-9EC8-46CA-869D-A1CFFF5C4AC8Q33678859-146D88B3-A459-400C-93BC-FB02D86EA38CQ34098512-BA3472B8-6C0A-474F-B587-7044A3FC3170Q34112933-5E7F6B59-EE20-4CB9-8F70-489B3EA6E881Q34239110-A004F35B-0381-488F-8B7E-C8F18EC57032Q34560975-9227D492-A0AD-4858-BA83-DA51D2BAFE3AQ34629707-DE0185B9-A0B2-406D-AC60-AC370AAEE005Q34645841-FC2A0D34-3285-4589-8F33-F306BD72D7A9Q34647657-560ACB38-3155-441B-B07C-361AD66CF64DQ35990486-B955CE9B-1F40-49F3-91EA-350A9607AE38Q36020276-D9FA6CC5-5590-4175-BF1B-F96DC1FA10C0Q36357993-C25A97B7-35BA-487A-B2F9-DDD5EF029FDFQ36397237-097A1247-55C8-4A2F-876C-94FAFB4E31BCQ36410784-95ADB926-EF97-44C9-ABC0-D7463B2C3124Q36629185-FCC6723E-A0E2-450C-85ED-943E37C6BB33Q36831009-136EA482-6D88-4AB9-BAFA-7B095AF2844BQ37071511-8EE41335-ED60-453D-BA74-A3A1A88997D1Q37082483-63589806-B3A5-4D2D-9E44-F8ACFD79B9F4Q38087564-C48AE152-ED92-4E3B-A982-EA7FCA5FD1BEQ38192959-9141CDD2-AEF8-4C59-90DF-A98036BE9169Q39221467-725FA855-C1AB-4311-A590-FFBB50144CDAQ39754329-60D4C765-3867-4155-B2DB-CB97AF89A3B3Q40359394-35AB75B1-4824-4ABA-8392-1EFA9189C127Q44252300-9074304B-A8AF-4EC4-AA86-4EB06A7D2E67Q44255973-74AA0D7B-51AF-4D94-817B-9D2F6E93F6CFQ45059993-40C2A0D3-894D-405D-8D02-C5F673A08AE6Q45238701-9686C206-C287-45A8-AF49-9EA9F0F0055FQ45261577-E22832EF-7BEC-459C-A7BA-715B98A62776Q46272702-213E3FD8-077D-4326-9C90-C794BE491DBB
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Altered states: the clinical effects of Ecstasy.
@ast
Altered states: the clinical effects of Ecstasy.
@en
type
label
Altered states: the clinical effects of Ecstasy.
@ast
Altered states: the clinical effects of Ecstasy.
@en
prefLabel
Altered states: the clinical effects of Ecstasy.
@ast
Altered states: the clinical effects of Ecstasy.
@en
P1476
Altered states: the clinical effects of Ecstasy
@en
P2093
P356
10.1016/S0163-7258(03)00003-2
P577
2003-04-01T00:00:00Z